This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hill-Rom (HRC) on product launches as well as solid third-quarter of fiscal 2020 results.
Quest Diagnostics Partners in Pilot Program for COVID-19 Test
by Zacks Equity Research
Quest Diagnostics (DGX) to provide online test results for COVID-19 samples collected via drone-delivered at-home self-collection kits as part of a pilot program.
Here's Why You Should Avoid Betting on Integer Holdings Now
by Zacks Equity Research
Stiff competition in the MedTech space and weak segmental and operational performance weighs on Integer Holdings (ITGR).
Cerner Inks Deal to Simplify Advance Care Planning Procedure
by Zacks Equity Research
Cerner's (CERN) partners with Vynca to simplify advance care planning process, thereby enabling patients and clinicians to discuss and make critical end-of-life decisions.
Top Analyst Reports for P&G, Verizon & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Verizon Communications (VZ) and Thermo Fisher Scientific (TMO).
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
NuVasive Banks on Product Launches Amid Procedural Volume Loss
by Zacks Equity Research
NuVasive (NUVA) is leaving no stone unturned to capture the fast-growing spine market.
Boston Scientific, Farapulse Sign Deal for Treatment of AF
by Zacks Equity Research
Boston Scientific (BSX) aims to provide a comprehensive portfolio of electrophysiology products and services via the latest investment agreement.
Abbott's MitraClip G4 Receives CE Mark for Treatment of MR
by Zacks Equity Research
Abbott's (ABT) MitraClip G4 is expected to improve MR patients' quality of life post its usage eligibility in Europe and other countries recognizing the CE Mark.
LabCorp Boosts Oncology Offerings With Resolution ctDx Launch
by Zacks Equity Research
This development comes on the heels of LabCorp's (LH) commercial partnership with non-invasive liquid biopsy platform developer, Resolution Bioscience.
Baxter's Clinimix and Clinimix E Injections Receive FDA Nod
by Zacks Equity Research
Baxter's (BAX) Clinimix and Clinimix E with Higher Protein Injection received FDA approval, which will help clinicians to improve care for critically ill patients.
Quest Diagnostics New Tests Uptake Strong Amid Coronavirus Woe
by Zacks Equity Research
Heavy demand for COVID-19 molecular testing helps partially offset the base volume decline for Quest Diagnostics (DGX).
Medtronic TYRX Driveline Gets FDA's Breakthrough Designation
by Zacks Equity Research
This development helps Medtronic (MDT) to augment its research work in the space of interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be positive about ResMed (RMD) owing to its robust product line and consistent high demand for its critical care products.
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $430.24, moving +1.12% from the previous trading session.
Here's Why You Should Avoid Betting on Intuitive Surgical Now
by Zacks Equity Research
Intense competition in the global MedTech space and weak operational performance weighs on Intuitive Surgical (ISRG).
Veeva's Offering Chosen by Idorsia to Drive Digital Engagement
by Zacks Equity Research
Veeva Systems' (VEEV) Commercial Cloud selected by Idorsia to enhance its digital field force in the United States, Japan and countries across Europe.
The Zacks Analyst Blog Highlights: MDRX, VEEV, DGX, TMO and ZM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MDRX, VEEV, DGX, TMO and ZM
The Zacks Analyst Blog Highlights: FMS, HOLX and TMO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: FMS, HOLX and TMO
Insulet's Omnipod DASH Shines, New Omnipod Uptake Slows Down
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation of the Omnipod 5 launch in 2021.
Abbott Launches Sports Biosensor in Europe, Boosts CGM Wing
by Zacks Equity Research
Abbott (ABT) makes its first non-exclusive collaboration with Atlanta-based sports technology company, Supersapiens.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with strength in its Life Sciences business.
Medtronic's (MDT) TYRX Envelope Study Results Encouraging
by Zacks Equity Research
Medtronic's (MDT) TYRX Envelope lowers infection risks and is cost-effective.
PRA Health (PRAH) Enters Into Strategic Deal With Deep Lens
by Zacks Equity Research
PRA Health's (PRAH) deal with Deep Lens can help detect and match oncology patients to suitable clinical trials and best precision therapies.
Here's Why You Should Retain Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.